Abstract:Introduction: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that widely affects motor neurons of the CNS. About 20% of patients with ALS have familial ALS (fALS). One of the classic models of ALS are SOD1 G93A mice. Misfolded SOD1 protein can be overexpressed in motor neurons, which results in progressive paralysis of the limbs of mice. There is still no effective treatment for ALS. In recent years, the treatment of ALS by regulating autophagy has become a research hotspot. Autophagy obstacles have been confirmed to be one of the early pathological events of ALS. Rab7 is a member of the Ras superfamily and plays a key role in the late stage of autophagy. In our previous studies, we found that prenoylation of Rab7 was inhibited in the ALS model. Prenylation is a post-translational modification in which farnesyl or geranylgeranyl groups are covalently linked to target proteins. Based on these findings, we proposed the novel idea that the regulation of RabGGTB (the β-subunit of RabGGTase) mediated prenylation modification of Rab7, and that this can be used as a prevention and treatment of ALS associated with abnormal protein accumulation. Methods: In the present study, RabGGTB was overexpressed in mouse spinal cord motoneurons by using adeno-associated virus as vector. Then immunofluorescence quantitative analysis was used for pathological study. The body weight, footprint analysis, the accelerating rotarod test, and neurological deficits score were used to evaluate animal behavior. Results: Our results show that the protein level of RabGGTB was significantly increased in the lumbar and thoracic regions of spinal cord motoneurons of injected mice. Furthermore, the onset time and survival time of SOD1 G93A mice injected with AAV9-RabGGTB-GFP + were delayed compared with those of mice without overexpression. At the same time, we also observed a decrease in SOD1 misfolded and glial overactivation in the lumbar spinal cord of these SOD1 G93A mice. Conclusion: The findings reported here show that RabGGTB plays a significant role in the pathogenesis of SOD1 G93A mice and with great therapeutic potential for reducing abnormal aggregation of SOD1 in ALS.

Desloratadine alleviates ALS-like pathology in hSOD1 G93A mice via targeting 5HTR 2A on activated spinal astrocytes

Pharmacological inhibition of ALCAT1 mitigates amyotrophic lateral sclerosis by attenuating SOD1 protein aggregation

Antiallergic drug desloratadine as a selective antagonist of 5HT 2A receptor ameliorates pathology of Alzheimer's disease model mice by improving microglial dysfunction

Roflupram alleviates autophagy defects and reduces mutant hSOD1 -induced motor neuron damage in cell and mouse models of amyotrophic lateral sclerosis

Slowing disease progression in the SOD1 mouse model of ALS by blocking neuregulin-induced microglial activation

A Novel Anti-Inflammatory d-Peptide Inhibits Disease Phenotype Progression in an ALS Mouse Model

Honokiol alleviated neurodegeneration by reducing oxidative stress and improving mitochondrial function in mutant SOD1 cellular and mouse models of Amyotrophic lateral sclerosis

Cromolyn sodium delays disease onset and is neuroprotective in the SOD1G93A Mouse Model of amyotrophic lateral sclerosis

Low-intensity pulsed ultrasound modulates disease progression in the SOD1G93A mouse model of amyotrophic lateral sclerosis

Low-intensity Pulsed Ultrasound Modulates Disease Progression in the SOD1G93Amouse G93A Mouse Model of Amyotrophic Lateral Sclerosis

BL-918, a small-molecule activator of ULK1, induces cytoprotective autophagy for amyotrophic lateral sclerosis therapy

Protective effects of intrathecal injection of AAV9-RabGGTB-GFP+ in SOD1G93A mice

R13 preserves motor performance in SOD1 G93A mice by improving mitochondrial function

Impaired glymphatic function in the early stages of disease in a TDP-43 mouse model of amyotrophic lateral sclerosis

Novel P2X7 Antagonist Ameliorates the Early Phase of ALS Disease and Decreases Inflammation and Autophagy in SOD1-G93A Mouse Model

PROTECTIVE EFFECTS OF RESVERATROL ON THE MUTANT hSOD1G93A-BEARING MOTOR NEURON-LIKE CELL CULTURE MODEL OF AMYOTROPHIC LATERAL SCLEROSIS THROUGH THE UPREGULATION OF SIRT1 EXPRESSION

Novel FKBP12 ligand promotes functional improvement in SOD1 ALS mice

Concurrent blockade of free radical and microsomal prostaglandin E synthase-1-mediated PGE2 production improves safety and efficacy in a mouse model of amyotrophic lateral sclerosis

Sex-dependent effects of the uncompetitive N-methyl-D-aspartate receptor antagonist REL-1017 in G93A-SOD1 amyotrophic lateral sclerosis mice

Beneficial and Sexually Dimorphic Response to Combined HDAC Inhibitor Valproate and AMPK/SIRT1 Pathway Activator Resveratrol in the Treatment of ALS Mice

Combination AAV therapy with galectin-1 and SOD1 downregulation demonstrates superior therapeutic effect in a severe ALS mouse model